bilijodon
iopanoic acid
CAS: 96-83-3
Molecular Formula: C11H12I3NO2
bilijodon - Names and Identifiers
| Name | iopanoic acid |
| Synonyms | choladine bilijodon Iopanoic acid iopanoic acid Iodopanoicacid Iodopanoic acid 2-(3-amino-2,4,6-triiodobenzyl)butyric acid 3-Amino-ethyl-2,4,6-triiodohydrocinnamicacid 2-(3-amino-2,4,6-triiodobenzyl)butanoic acid 3-Amino-ethyl-2,4,6-triiodobenaenepropanoicacid 3-amino-alpha-ethyl-2,4,6-triiodo-hydrocinnamicaci 3-amino-alpha-ethyl-2,4,6-triiodobenzenepropanoicacid 3-amino-alpha-ethyl-2,4,6-triiodo-benzenepropanoicaci beta-(3-amino-2,4,6-triiodophenyl)-alpha-ethylpropionicacid |
| CAS | 96-83-3 |
| EINECS | 202-539-9 |
| InChI | InChI=1/C11H12I3NO2/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5H,2-3,15H2,1H3,(H,16,17) |
bilijodon - Physico-chemical Properties
| Molecular Formula | C11H12I3NO2 |
| Molar Mass | 570.93 |
| Density | 2.2567 (estimate) |
| Melting Point | 153 °C |
| Boling Point | 529.1±50.0 °C(Predicted) |
| Flash Point | 273.8°C |
| Water Solubility | 348.3mg/L(37 ºC) |
| Solubility | DMSO, Methanol |
| Vapor Presure | 5.06E-12mmHg at 25°C |
| Appearance | neat |
| Color | Light Brown |
| Merck | 14,5058 |
| pKa | 4.8(at 25℃) |
| Storage Condition | 2-8°C |
| Refractive Index | 1.732 |
| MDL | MFCD00038687 |
| Physical and Chemical Properties | White or milky white powder. Melting point 155-157 ℃. Soluble in sodium hydroxide or sodium carbonate solution, 95% ethanol, chloroform or ether, insoluble in water. Almost tasteless, with a slight peculiar odor. |
| Use | Diagnostic medication, for myelography |
bilijodon - Risk and Safety
| Risk Codes | 20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
| Safety Description | S22 - Do not breathe dust. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
| WGK Germany | 1 |
| RTECS | NW5075000 |
bilijodon - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.752 ml | 8.758 ml | 17.515 ml |
| 5 mM | 0.35 ml | 1.752 ml | 3.503 ml |
| 10 mM | 0.175 ml | 0.876 ml | 1.752 ml |
| 5 mM | 0.035 ml | 0.175 ml | 0.35 ml |
Last Update：2024-01-02 23:10:35
bilijodon - Reference Information
| is a positive contrast agent for X-ray diagnosis | iodophanic acid, English name Iopanoic Acid, molecular formula is C11H12I3NO2, this product is an organic iodine compound, is a positive contrast agent for X-ray diagnosis. After oral administration, it mainly flows into the gallbladder with concentration function through the liver. After concentration, the shape and function of the gallbladder are displayed under X-ray. Through the concentration of the contrast agent in the bile by the gallbladder, the contrast is improved, so that the gallbladder can be displayed specifically. The method of cholecystography can effectively check gallbladder diseases. The iodine slowly released by this product during metabolism in the body has the effect of inhibiting the release of thyroid hormones by thyroid follicular cells, so it has the effect of quickly controlling hyperthyroidism, and the side effects of the drug on the human body are very small. Therefore, this product is ideal as an auxiliary drug for the treatment of hyperthyroidism, especially for patients with severe hyperthyroidism and hyperthyroidism with thyroid heart disease, and anti-hyperthyroidism drugs are allergic or unable to control clinical symptoms. Fig. 1 shows the structural formula of iodophanic acid |
| pharmacological action | 1. improve the diagnosis and treatment level of gallbladder stones. for stones with the same density as bile, plain CT scan cannot find them, and can only be displayed with the help of oral iodophanic acid contrast agent, the typical CT manifestation is the filling defect shadow that moves with the change of body position. Therefore, oral iodofan acid cholecystography CT makes up for the deficiency of CT plain scan in the display of isodense stones and improves the diagnostic level. 2. Improve the detection rate of gallbladder polypoid lesions. The detection rate of gallbladder polyps and adenomas using CT plain scan is low, and the detection rate of CT after oral administration of the drug is significantly improved, especially now there are still some difficulties in the identification of small focal lesions. Gallbladder adenomyomatosis C T plain scan lacks characteristics, and the cholecystography CT of oral administration of this product sometimes shows the characteristic rosette sign, which is the interwall diverticulum of contrast agent, which can make a clear diagnosis. 3. Distinguish gallbladder and non-gallbladder lesions. After oral administration of this product, contrast agent filling can be seen in the oval shape with slightly high density shadow, thus diagnosing cholecystitis. In addition, the developed gallbladder can also be used to determine the origin of the lesion or the relationship between the lesion and the gallbladder. For example, when the boundary between the lesion in the gallbladder fossa and the gallbladder is unclear, and when it is difficult to distinguish between gallbladder cancer and liver cancer, the existence of this product is very important. |
| pharmacokinetics | this product is an oral gallbladder contrast agent. after oral administration, it is insoluble in the stomach, mostly dissolved in alkaline intestinal fluid, then absorbed, and a small part remains in the intestinal tract, affecting gallbladder and cholangiography. The sodium salt of this product is completely absorbed and enters the blood circulation through the portal vein. About 80% of it is secreted into the bile from the liver. After 4 hours of oral administration, the drug appears in the bile. The iodine content in the unconcentrated bile is about 0.3%,12 ~ After 14 hours, it can be concentrated to about 2% in the gallbladder, and it can be clearly developed at this time. It is then drained from the bile duct into the intestine. This product is mainly excreted by feces and kidneys. Generally, 50% can be excreted within 24 hours, and all excreted for more than 5 days. |
| indications | this product is taken orally as gallbladder contrast agent, which is absorbed in intestinal tract and circulated through portal vein. Part of the bile is secreted into the liver, which is concentrated and developed by the gallbladder. It can be used for the diagnosis of gallbladder stones and diseases such as gallbladder wall lesions; this product is ideal as an auxiliary drug for the treatment of hyperthyroidism, and has the effect of rapid control of hyperthyroidism, Especially for patients with severe hyperthyroidism and hyperthyroidism with thyroid heart disease, as well as patients with anti-hyperthyroidism drugs allergic or unable to control clinical symptoms. |
| dosage and usage | this product is an oral drug with different dosage for different uses. 1. Eat high-fat food at noon on the day of routine gallbladder radiography, use a small amount (avoid fat) for dinner, swallow this product with warm boiled water at 8-10 pm, take one tablet every 5 minutes, take a total of 6 tablets, take 30 minutes after oral administration, and fast fat before taking the tablet at 8-10 am the next day. 2. Gallstone radiography This product can be combined with bilirubin or biliverdin and stained for gallstone staining radiography. Usage, 0.5g each time from the first 1 to 4 days, 3 times a day, 1g each time on the 5th, 3 times a day, 9g in total. |
| adverse reactions | 1. mild nausea, vomiting, diarrhea and other gastrointestinal reactions after taking the service; 2. mild urine burning sensation and pseudoproteinuria and other reactions. |
| precautions | 1. iodine allergy test should be done before taking. 2. On the morning of the radiography, Kaisailu can be used for laxative (laxatives are not allowed), which can reduce the fecal shadow in the X-ray film and help to observe the gallbladder shadow. 3. Severe liver and kidney dysfunction and acute gastrointestinal dysfunction are prohibited. The pharmacological effects, pharmacokinetics, indications, precautions, etc. of iodophanic acid are edited by Bao Quan. (2016-01-22) |
| chemical properties | white or milky white powder. Melting point 155-157 ℃. Soluble in sodium hydroxide or sodium carbonate solution, 95% ethanol, chloroform or ether, insoluble in water. Almost tasteless, with a slight peculiar odor. |
| use | this product is a diagnostic drug. diagnostic medication for myelography |
| production method | obtained by condensation, reduction, acidification and iodination of m-nitrobenzaldehyde (see C7H5NO3,[99-61-6]). 1. Condensation Add n-butyrate anhydride and dried n-butyrate sodium to a dry reaction pot, stir and heat to remove moisture. Add m-nitrobenzaldehyde and react at 135-140 ℃ for about 7 hours. Cool and put into ice water to precipitate dark brown precipitate. Filter, wash the coke oil to obtain crude condensate. Dissolve it in dilute ammonia water, heat and decolorize the white clay with activated carbon under stirring, and crystallize the filtrate after filtration with dilute sulfation. Filtration, washing the filter cake with water, drying to obtain m-nitro-α-ethyl cinnamic acid (C11H11NO4), which is a light yellow crystal with a melting point of 141-143 ℃ and a yield of more than 70%. 2. Harvest, acidify, dissolve m-nitro-α-ethyl cinnamic acid in sodium hydroxide solution, heat to 75 ℃, gradually add aluminum-nickel alloy and aluminum powder under stirring, control the temperature at 80-84 ℃, after feeding, continue to heat preservation reaction for 0.5h. After reaching the finish line, filter. The filtrate is acidified with hydrochloric acid, precipitated and filtered, and the filter cake is metaamino-α-ethylphenylpropanoic acid hydrochloride (C11H15NO2 · HCL). 3. Iodination adds dichloroethane to the aqueous solution of metaamino-α-ethylphenylpropionic acid, and adds monochlorinated iodide acid solution under stirring for reaction. The obtained crude product is refined with dichloroethane to obtain iodofan acid. |
| EPA chemical information | The information is: ofmpub.epa.gov provides (external link) |
| toxic substance data | The information is: pubchem.ncbi.nlm.nih.gov Provide (external link) |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: 2-(3-Amino-2,4,6-Triiodobenzyl)Butyric Acid Visit Supplier Webpage Request for quotationCAS: 96-83-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: 2-(3-Amino-2,4,6-Triiodobenzyl)Butyric Acid Visit Supplier Webpage Request for quotationCAS: 96-83-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History